Cytosorbents (CTSO) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue was $8.7 million, down 3% year-over-year, with international growth offsetting a temporary disruption in Germany due to sales team realignment.

• Gross margin held steady at 71% (71.1%), down from 76–77% in Q1 2024, reflecting disciplined pricing and lower production volumes.

• Operating loss improved by 17% to $3.9 million, driven by a 12% reduction in operating expenses.

• Net loss narrowed significantly to $1.5 million ($0.02/share) from $6.1 million ($0.11/share) in Q1 2024; adjusted EBITDA loss improved by 17% to $2.7 million.

• Strategic focus remains on returning German sales to growth, expanding in the Middle East via Dubai, and preparing for DrugSorb-ATR launch in North America.

Financial highlights

• Q1 2025 product sales: $8.7 million, down 3% year-over-year; gross profit was $6.2 million (71% margin), down 10% year-over-year.

• Operating expenses fell to $10.1 million, a 12% decrease year-over-year.

• Net loss: $1.5 million ($0.02/share), improved from $6.1 million ($0.11/share) prior year; adjusted net loss was $3.7 million ($0.06/share).

• Adjusted EBITDA loss: $2.7 million, improved from $3.3 million year-over-year.

• Cash, cash equivalents, and restricted cash: $13.1 million as of March 31, 2025, up from $9.8 million at year-end.

Outlook and guidance

• Expectation to return German sales to growth in H2 2025 after strategic reorganization.

• Anticipate gross margin expansion with increased production and smoother operations.

• Core business targeted to approach cash flow break-even by H2 2025.

• Preparing for potential DrugSorb-ATR launch in the U.S. and Canada, pending regulatory approval; regulatory decisions expected in 2025.

• Management anticipates stronger adoption and usage of CytoSorb based on new clinical evidence and training initiatives.